Arazyme inhibits cytokine expression and upregulates skin barrier protein expression

  • Authors:
    • In Sik Kim
    • Mi Jin Kim
    • Dong‑Ha Shin
    • Kwang‑Hee Son
    • Ho‑Yong Park
    • Ji‑Sook Lee
  • View Affiliations

  • Published online on: June 13, 2013     https://doi.org/10.3892/mmr.2013.1520
  • Pages: 551-556
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present study, the inhibitory effect of arazyme on allergic inflammation was investigated by evaluating the alteration of cytokine production and expression of skin barrier proteins in immune and HaCaT human keratinocyte cells. THP‑1 human monocytic and EoL‑1 human eosinophilic cells were treated with Dermatophagoides pteronissinus extract (DpE). Monocyte chemotactic protein‑1 (MCP‑1)/CCL2, interleukin (IL)‑6 and IL‑8 increased following DpE treatment and arazyme significantly blocked the increase of MCP‑1, IL‑6 and IL‑8 expression in cell types. Secretion of MCP‑1, IL‑6 and IL‑8 induced by lipopolysaccharide in THP‑1 cells was also inhibited by arazyme treatment. Arazyme inhibited the secretion of IL‑6 and IL‑8 due to phorbol 12‑myristate 13‑acetate and calcium ionophores in human mast cells. Arazyme blocked the secretion of thymus and activation‑regulated chemokine (TARC)/CCL17, MCP‑1, IL‑6 and IL‑8 due to tumor necrosis factor‑α (TNF‑α) and interferon‑γ (IFN‑γ) in HaCaT cells. TNF‑α and IFN‑γ suppressed the expression of skin barrier proteins, including filaggrin, involucrin and loricrin. By contrast, arazyme increased the expression of filaggrin, involucrin and loricrin. These results may contribute to the development of a therapeutic drug for the treatment of allergic diseases, including atopic dermatitis.
View Figures
View References

Related Articles

Journal Cover

August 2013
Volume 8 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim IS, Kim MJ, Shin DH, Son KH, Park HY and Lee JS: Arazyme inhibits cytokine expression and upregulates skin barrier protein expression. Mol Med Rep 8: 551-556, 2013
APA
Kim, I.S., Kim, M.J., Shin, D., Son, K., Park, H., & Lee, J. (2013). Arazyme inhibits cytokine expression and upregulates skin barrier protein expression. Molecular Medicine Reports, 8, 551-556. https://doi.org/10.3892/mmr.2013.1520
MLA
Kim, I. S., Kim, M. J., Shin, D., Son, K., Park, H., Lee, J."Arazyme inhibits cytokine expression and upregulates skin barrier protein expression". Molecular Medicine Reports 8.2 (2013): 551-556.
Chicago
Kim, I. S., Kim, M. J., Shin, D., Son, K., Park, H., Lee, J."Arazyme inhibits cytokine expression and upregulates skin barrier protein expression". Molecular Medicine Reports 8, no. 2 (2013): 551-556. https://doi.org/10.3892/mmr.2013.1520